Cutaneous adverse drug reaction after continuous subcutaneous apomorphine infusion

Abstract

breastfeeding period was uncomplicated during the next 4 months of observational period. The European Medicines Agency (EMA) reported 2017 data from one phase-2b and three phase-3 studies including 2500 AE patients, whereby 23 pregnancies of female patients treated with dupilumab resulted in deliveries of eight healthy babies (1 twin birth), two induced abortions and six spontaneous abortions. In two of these six cases, patients had at least one risk factor for abortion (i.e. elevated parathyroid hormone, clotting disorders and history of infertility). Five pregnancies were still ongoing at that point, and three pregnancies were lost to follow-up. 8 In the EMA assessment report for the indication expansion of dupilumab in treatment for asthma published in 2019, nineteen pregnancies were reported from one phase-2b and two phase-3 studies. Pregnancies resulted in eight healthy babies (one twin birth), one baby with Turner's syndrome, five spontaneous and three induced abortions. Of the five spontaneous abortions, three patients had at least one risk factor for abortion (i.e. clotting disorders, infertility treatments, advanced age and twin pregnancy). Three pregnancies were still ongoing. The spontaneous abortion rate did not exceed the general spontaneous abortion rate. 9 Accordingly, until today, neither clinical nor experimental data nor theoretical considerations point to dupilumab's teratogenic capacity. However, the ETAD advises that other systemic drugs should be used instead of dupilumab in pregnant women with AE until more experience is available. 6 Our case supports the idea that dupilumab may be used after careful risk-benefit assessment in pregnancy and lactation if all other therapies have failed. There was no funding to support this work.

Continuous Subcutaneous Infusion Delivery of Apomorphine in Parkinson's Disease: A Systematic Review

“…Common published adverse events of CSAI in major case series and case reports are listed in Table 4 and Table S1 18,22,24–26,29,52–71 . In an audit on reasons for discontinuing therapy of 107 patients over 10 years, Tyne et al 18 reported that therapy was discontinued in 16% of patients (with some opting for intermittent injections, and 10 going on to DBS).…”

“…Common published adverse events of CSAI in major case series and case reports are listed in Table 4 and Table S1. 18,22,[24][25][26]29,[52][53][54][55][56][57][58][59][60][61][62][63][64][65][66][67][68][69][70][71] In an audit on reasons for discontinuing therapy of 107 patients over 10 years, Tyne et al 18 reported that therapy was discontinued in 16% of patients (with some opting for intermittent injections, and 10 going on to DBS). Although nine patients died during the audit periods, none of the deaths were attributed to CSAI.…”